Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 23:13:994253.
doi: 10.3389/fimmu.2022.994253. eCollection 2022.

Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study

Affiliations

Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study

Terese L Katzenstein et al. Front Immunol. .

Abstract

The risk of severe adult respiratory coronavirus-2 (SARS-CoV-2) infection and the course of the infection among individuals with common variable immunodeficiency (CVID) relative to the general population have been a matter of debate. We conducted a Danish nationwide study comparing the timing of SARS-CoV-2 vaccination, the risk of first confirmed SARS-CoV-2 infection, re-infection, and the outcome of infection among individuals with CVID relative to an age- and gender matched control group. Cox regression was used to calculate incidence rate ratios. The CVID patients received SARS-CoV-2 vaccinations earlier than those included in the population control group. Even so, the risks of both first infection and re-infection were increased among the individuals with CVID. The CVID group also had increased risk for hospital contacts due to SARS-CoV-2 infection relative to the general population. However, reassuringly, the risk of mechanical ventilation and death did not differ between the groups, but the numbers were low in both groups, making the estimates uncertain. Though this is the largest study to investigate the risk of SARS-CoV-2 infections and outcomes hereof among individuals with CVID relative to the general population, we cannot rule out minor differences in severity, which might only be detectable with an even larger sample size.

Keywords: clinical outcome; common variable immunodeficiency (CVID); inborn errors of immunity (IEI); severe adult respiratory coronavirus-2 (SARS-CoV-2); severe novel coronavirus 2019 (COVID-19).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Time to second and third SARS-COV-2 vaccination. Black lines: population controls, gray lines: CVID patients. Solid lines: second vaccination, dotted lines: third SARS-CoV-2 vaccination. Time starts on January 1, 2020 and ends on May 1, 2022.
Figure 2
Figure 2
Time to first and second positive SARS-CoV-2 test. Solid lines: first positve test, dotted line: second positive SARS-CoV-2 test. Black lines: population controls, gray lines: CVID patients.
Figure 3
Figure 3
(A) First hospital contact with COVID-19. Solid line: population controls, dotted line: CVID patients. Time starts on 1 March 2020. (B) Time to first hospitalizations with severe COVID-19, Solid line: population cointrol, dotted line: CVID patients. Time starts on 1 March 2020. (C) Time to hospitalization after the first positive SARS-CoV-2 test. Solid line: population controls, dotted line: CVID patients. Time starts on date of first positive SARS-CoV-2 test.

References

    1. Liu BM, Hill HR. Role of host immune and inflammatory responses in COVID-19 cases with underlying primary immunodeficiency: A review. J Interferon Cytokine Res (2021) 142:155478 doi: 10.1089/jir.2020.0210 - DOI - PMC - PubMed
    1. AlShanableh Z, Haidous M, Wong KM, Al-Saed M, Altaqi B. Immunodeficiency: A protective factor for COVID-19? Cureus (2022) 14(7):e27177. doi: 10.7759/CUREUS.23094 - DOI - PMC - PubMed
    1. Goudouris ES, Pinto-Mariz F, Mendonça LO, Aranda CS, Guimarães RR, Kokron C, et al. . Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: A cross-sectional study. J Clin Immunol (2021) 41:1479–89. doi: 10.1007/S10875-021-01066-8 - DOI - PMC - PubMed
    1. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O PM, Zermeño DM, Mendoza SSC, Montoya EM, et al. . COVID-19 in the context of inborn errors of immunity: A case series of 31 patients from Mexico. J Clin Immunol (2021) 41(7):1463–78. doi: 10.1007/s10875-021-01077-5 - DOI - PMC - PubMed
    1. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. . Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. Front Immunol (2021) 11:614086. doi: 10.3389/fimmu.2020.614086 - DOI - PMC - PubMed

Substances